Home Cart Sign in  
Chemical Structure| 1914078-41-3 Chemical Structure| 1914078-41-3

Structure of eCF506
CAS No.: 1914078-41-3

Chemical Structure| 1914078-41-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

eCF506 is a potent, orally active inhibitor of the non-receptor tyrosine kinase Src, with an IC50 value of <0.5 nM.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of eCF506

CAS No. :1914078-41-3
Formula : C26H38N8O3
M.W : 510.63
SMILES Code : NC1=C2C(C3=CC(OC)=C(NC(OC(C)(C)C)=O)C=C3)=NN(CCN4CCC(N(C)C)CC4)C2=NC=N1
MDL No. :MFCD31657410

Safety of eCF506

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Related Pathways of eCF506

RTK

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
5637 cells 100 nM 72 hours To evaluate the enhanced effect of eCF506 combined with cisplatin on apoptosis and cell death rates in 5637 cells. Results showed that eCF506 synergized with cisplatin to significantly increase apoptosis and cell death rates in 5637 cells. Commun Biol. 2025 Jan 10;8(1):36
T24 cells 100 nM 24 hours To evaluate the inhibitory effect of eCF506 on the proliferation, migration, and invasion of bladder cancer cells. Results showed that eCF506 significantly inhibited the proliferation, colony formation, migration, and invasion of T24 cells and arrested the cell cycle in the G0/G1 phase. Commun Biol. 2025 Jan 10;8(1):36
MCF7 0.1 µmol/L 5 days To evaluate the effect of eCF506 on proliferation of ER+ breast cancer cells, results showed eCF506 exhibited higher anti-proliferative activity in ER+ cell lines. Cancer Res. 2021 Nov 1;81(21):5438-5450
MDA-MB-231 0.1 µmol/L 6 hours To study the effect of eCF506 on SRC-FAK complex formation, results showed eCF506 decreased the recovery of FAK protein by 50%. Cancer Res. 2021 Nov 1;81(21):5438-5450
MDA-MB-231 40 nmol/L 72 hours To evaluate the sensitivity of ILK knockout cells to eCF506, results showed that ILK knockout enhanced the inhibitory effect of eCF506. Cancer Res. 2022 Feb 15;82(4):632-647
MDA-MB-231 cells 1-10,000 nM 5 days Evaluate the inhibitory effect of compounds on MDA-MB-231 cell proliferation J Med Chem. 2016 May 26;59(10):4697-710
MCF7 cells 100 μM 5 days Evaluate the inhibitory effect of compounds on MCF7 cell proliferation J Med Chem. 2016 May 26;59(10):4697-710

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice HCT116 xenograft model Oral 50 mg/kg Once daily for 3 days Evaluate the inhibitory effect of eCF506 on SRC phosphorylation in vivo J Med Chem. 2016 May 26;59(10):4697-710
C57BL/6 mice Cell-derived xenograft model (CDX) Intraperitoneal injection 20 mg/kg Every 2 days until the end of the experiment To evaluate the anti-tumor effect of eCF506 in the CDX model. Results showed that eCF506 significantly inhibited tumor growth, and no obvious adverse effects were observed. Commun Biol. 2025 Jan 10;8(1):36
Mice Inducible Slc4a11 knockout mouse model Eye drop administration 1 μM Three times daily for 14 days Inhibited Src kinase activity, slowed corneal edema, improved barrier function, reduced lactate accumulation, and restored tight junction and cortical cytoskeleton structures Cells. 2023 Jun 1;12(11):1528
Mice Breast cancer model Oral 40 mg/kg Once daily for 28 days To evaluate the antitumor effect of eCF506 in immunocompetent mice, results showed potent antitumor activity during the treatment phase and delayed tumor relapse post-treatment. Cancer Res. 2021 Nov 1;81(21):5438-5450
Immunodeficient Rag2-Il2rg double knockout mice MDA-MB-231 xenograft model Oral gavage 40 mg/kg body weight Once daily for 35 days To evaluate the growth inhibitory effect of eCF506 on ILK knockout tumors, results showed that eCF506 completely blocked the growth of ILK knockout tumors. Cancer Res. 2022 Feb 15;82(4):632-647

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.96mL

0.39mL

0.20mL

9.79mL

1.96mL

0.98mL

19.58mL

3.92mL

1.96mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories